General American Investors Co. Inc. Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN

General American Investors Co. Inc. grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 217.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 31,362 shares of the biopharmaceutical company’s stock after acquiring an additional 21,486 shares during the quarter. Regeneron Pharmaceuticals accounts for 1.0% of General American Investors Co. Inc.’s portfolio, making the stock its 29th biggest holding. General American Investors Co. Inc.’s holdings in Regeneron Pharmaceuticals were worth $17,634,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently modified their holdings of the company. Brighton Jones LLC increased its stake in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after purchasing an additional 686 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $226,000. CX Institutional increased its position in shares of Regeneron Pharmaceuticals by 7.9% during the second quarter. CX Institutional now owns 302 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 22 shares in the last quarter. Patton Fund Management Inc. purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $210,000. Finally, Avior Wealth Management LLC lifted its position in Regeneron Pharmaceuticals by 66.0% in the 2nd quarter. Avior Wealth Management LLC now owns 1,461 shares of the biopharmaceutical company’s stock valued at $767,000 after acquiring an additional 581 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the subject of a number of research analyst reports. Hsbc Global Res raised Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 24th. UBS Group lifted their price objective on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a report on Friday, November 7th. Citigroup raised their price target on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday, December 29th. Finally, Evercore ISI increased their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a research report on Thursday, January 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $784.77.

Insider Activity

In other news, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. This represents a 46.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the transaction, the director owned 2,352 shares in the company, valued at $1,538,843.04. This trade represents a 73.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 8,431 shares of company stock valued at $5,733,521 in the last 90 days. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $762.65 on Tuesday. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. The company has a market cap of $80.15 billion, a price-to-earnings ratio of 18.26, a PEG ratio of 1.96 and a beta of 0.39. The company’s 50 day moving average is $756.55 and its 200 day moving average is $645.80. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. During the same period in the prior year, the company earned $12.46 earnings per share. The firm’s revenue was up .9% on a year-over-year basis. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.